April 2022: The Chinese Obstetricians and Gynaecologists Association (COGA) completed a much anticipated, detailed cervical cancer screening trial that commenced in September 2018 and completed in July 2021. The results of this trial have just been released and presented at a research conference organised by ASCCP (American Society of Colposcopy and Cervical Pathology) held in San Diego, USA. It compared the relative effectiveness of TruScreen (NZX/ASX:TRU) against two other cervical cancer screening methods of HPV DNA testing (HPV) and Liquid Based Cytology (LBC).
Read the full announcement:
_________________________________
Learn more: www.truscreen.com
TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening technologies that have only triage/adjunct functionality, the TruScreen device is registered as a primary screening tool.
TruScreen’s cervical screening technology effectively resolves many of the ongoing issues with conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure.
The device is CE-marked, meaning it meets EU safety, health and environmental protection standards required for sale and use throughout Europe. It is also National Medical Products Administration approved for sale in China.
TruScreen is currently targeting product sales to a range of low and middle-income countries, including China, Mexico, Vietnam, Russia, and Saudi Arabia, where no large-scale cervical cancer screening programs and infrastructure are currently in place. By doing so, the Company hopes to help improve the health and wellbeing of women worldwide.
Негізгі бет Ғылым және технология COGA Trial validates superiority of TruScreen cervical cancer screening method
Пікірлер